The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue

Patrizia Chiusolo, Nicola Piccirillo, Luca Laurenti, Stefan Hohaus, Simona Sica, Sabrina Giammarco, Silvia Bellesi, Elisabetta Metafuni, Daniela Giovanna De Ritis, Sara Marietti, Luana Fianchi, Giuseppe Leone, S Federica

Risultato della ricerca: Contributo in rivistaArticolo in rivista

31 Citazioni (Scopus)

Abstract

In the last years, the influence of different genes involved in metabolism of chemotherapeutic agents has been studied. Methotrexate (MTX) is a key compound of chemotherapeutic regimens used in the treatment of acute lymphoblastic leukemia (ALL), primary central nervous system lymphoma (PCNSL) and Burkitt's lymphomas (BL). This study aims to evaluate the role of MTHFR C677T and A1298C polymorphisms and G80A reduced folate carrier gene (RFC1) in a cohort of adult patients with lymphoproliferative malignancies submitted to high-dose MTX followed by leucovorin rescue.
Lingua originaleEnglish
pagine (da-a)691-696
Numero di pagine6
RivistaCancer Chemotherapy and Pharmacology
Volume69
DOI
Stato di pubblicazionePubblicato - 2012

Keywords

  • Adolescent
  • Adult
  • Aged
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols
  • Cohort Studies
  • Disease-Free Survival
  • Hematologic Neoplasms
  • Humans
  • Kaplan-Meier Estimate
  • Leucovorin
  • Male
  • Methotrexate
  • Methylenetetrahydrofolate Reductase (NADPH2)
  • Middle Aged
  • Polymorphism, Genetic
  • Reduced Folate Carrier Protein
  • Young Adult

Fingerprint

Entra nei temi di ricerca di 'The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue'. Insieme formano una fingerprint unica.

Cita questo